Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $161K fell 35.9% year over year, behind the -21.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.

Context

  • Depreciation & amortization amounted to 55.1% of revenue in FY2025, down 44.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -35.9% toward the trailing-twelve-month pace of -21.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$161K-13.4% QoQ
Last fiscal yearDec 2025
$900K-12.5% YoY
LTMMar 2026
$810K-21.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.9%——
1 year-12.5%——
3-year CAGR+18.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
900K USD
Year-over-year change
-12.5%
4-year CAGR
+16.0%

Depreciation & Amortization vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.4% is the 6th highest of 9, against a peer median of -0.1%.
  • Depreciation & amortization amounts to 25.6% of revenue for RANI, versus a peer median of 19.0%.
RANI Competitors
Depreciation & Amortization for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$6.56M USD-25.2%-28.2%19.0%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.37M CHF+2.1%-3.5%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$1.99M USD-26.5%+15.4%11.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$1.17M USD+120.2%+56.5%222.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.14M USD-2.3%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$810K USD-21.4%+18.0%25.6%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$287K USD-146.9%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$143K USD+37.5%+8.6%8.0%
Peer median (excluding RANI) —-0.1%+2.2%19.0%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.